BioSight
Companies
ENANTA PHARMACEUTICALS INC logo

ENTA

NASDAQWATERTOWN, MA
ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals is a biotechnology company developing small molecule drugs in virology and immunology. In virology, Enanta discovered glecaprevir (used in the marketed HCV drug MAVYRET) and has clinical-stage programs targeting RSV, COVID-19, and hepatitis B; in immunology, they're developing oral inhibitors targeting KIT and STAT6 to treat type 2 inflammatory diseases like atopic dermatitis, urticaria, and asthma, with several programs in early to mid-stage development.

Price history not yet available for ENTA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar